Taysha Gene Therapies Files Form 8-K Current Report With SEC on November 12

Updated

Taysha Gene Therapies, Inc. filed a Form 8-K current report with the U.S. Securities and Exchange Commission on November 12, 2026, according to an SEC EDGAR listing published that day. The EDGAR listing includes only the filer name and no filing contents, so the reason for the filing and any financial impact are not known. No market reaction was reported.

Sources:SEC EDGAR Current 8-K Filings (all issuers)

1 outlet · 1 article · first seen Nov 12, 7:40 AM ET

What this touches in markets

Stored closes for the instruments tied to this story's tags and places, with their dates.

XLV closed at 188.95, up 0.04%, on 2026-11-11. Listed for: Health Care sector ETF.

Every source article

8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer) SEC EDGAR Current 8-K Filings (all issuers)